Related references
Note: Only part of the references are listed.Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models
Mansoureh Sameni et al.
CLINICAL CANCER RESEARCH (2016)
Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis
Dale Miles et al.
CLINICAL PHARMACOKINETICS (2016)
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
L. Zhou et al.
ONCOGENE (2016)
Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults
Linh Nguyen et al.
ANTI-CANCER DRUGS (2016)
Population pharmacokinetic/pharmacodynamic modeling of tumor growth kinetics in medullary thyroid cancer patients receiving cabozantinib
Dale R. Miles et al.
ANTI-CANCER DRUGS (2016)
A Drug Interaction Between Cabozantinib and Warfarin in a Patient With Renal Cell Carcinoma
William Travis Foxx-Lupo et al.
CLINICAL GENITOURINARY CANCER (2016)
Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib
Linh Nguyen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2016)
Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition
Linna Zhang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors
Noah A. Cohen et al.
CANCER RESEARCH (2015)
Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects
Linh Nguyen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK
Linh Nguyen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Potent antitumor activity of cabozantinib, a c- MET and VEGFR2 inhibitor, in a colorectal cancer patient- derived tumor explant model
Eun-Kee Song et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein
Qing-feng Xiang et al.
LIVER INTERNATIONAL (2015)
Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites
Steven Lacy et al.
DRUG METABOLISM AND DISPOSITION (2015)
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
T. K. Choueiri et al.
ANNALS OF ONCOLOGY (2014)
Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone Lesions
Jinlu Dai et al.
CLINICAL CANCER RESEARCH (2014)
Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
Qingfeng Xiang et al.
CLINICAL CANCER RESEARCH (2014)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer
Frauke Bentzien et al.
THYROID (2013)
Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
Barbara Sennino et al.
CANCER DISCOVERY (2012)
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
Razelle Kurzrock et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Peter Carmeliet et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
MET signalling: principles and functions in development, organ regeneration and cancer
Livio Trusolino et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Targeting the Met signaling pathway in renal cancer
Alessio Giubellino et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Metastatic Renal Cell Carcinoma: Many Treatment Options, One Patient
Brian I. Rini
JOURNAL OF CLINICAL ONCOLOGY (2009)
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors
Michael L. Nickerson et al.
CLINICAL CANCER RESEARCH (2008)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Met, metastasis, motility and more
C Birchmeier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Share Paper
